nba ゲーム E-Gel  News release  Otsuka Pharmaceutical Factory launches a vasopressin V₂-receptor antagonist "Tolvaptan OD tNBAライブベッティングlets 7.5 mg Otsuka"

June 17, 2022

Otsuka Pharmaceutical Factory launches a vasopressin V₂-receptor antagonist "Tolvaptan OD tNBAライブベッティングlets 7.5 mg Otsuka"

Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: Shinichi Ogasawara; "OPF") announces that "Tolvaptan OD tNBAライブベッティングlets 7.5 mg Otsuka" (nonproprietary name: tolvaptan), a vasopressin V2-recepNBAライブベッティングr antagonist, has been listed in the National Health Insurance (NHI) drug price list and launched NBAライブベッティングday. NBAライブベッティングlvaptan received regulaNBAライブベッティングry approval on February 15, 2022.

Tolvaptan is an authorized generic drug with the same drug substance and additives manufactured uNBAライブベッティングng the same methods in the same factory as "Samsca® OD tNBAライブベッティングlets 7.5 mg," which is a new dosage form of the vasopressin V2-recepNBAライブベッティングr antagonist "Samsca®." Samsca was discovered and developed by our group company Otsuka Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; PreNBAライブベッティングdent and Representative Director: Makoto Inoue) and launched in December 2010.

Tolvaptan is a therapeutic agent that selectively blocks the binding of vasopresNBAライブベッティングn to the V2-receptors in the collecting duct of the kidney, thereby increasing the excretion of free water and reducing the re-NBAライブベッティングsorption of water from urine into the blood without directly affecting the excretion of sodium and other electrolytes. Tolvaptan was launched for the treatment of excess water retention in patients with hepatic cirrhosis when the treatment with other diuretics including loop diuretics is ineffective.

OPF, as a leading IV solution company, has an extenNBAライブベッティングve network from acute care hospitals to home health care through regular viNBAライブベッティングts to various clinical departments. We will continue to contribute to patients and healthcare profesNBAライブベッティングonals by providing products and detailed information.

Based on the corporate philosophy of "Otsuka-people creating new products for better health worldwide," the Otsuka Group is dedicated NBAライブベッティング contributing NBAライブベッティング the health of people around the world.

Product NBAライブベッティングformation

Brand name

Tolvaptan OD tNBAライブベッティングlets 7.5 mg Otsuka

Generic name

NBAライブベッティングlvaptan

NBAライブベッティングdications

Treatment of excess water retention in patients with hepatic cirrhoNBAライブベッティングs when the treatment with other diuretics including loop diuretics is ineffective.

Dosage and

admNBAライブベッティングistration

The usual adult dosage is 7.5 mg of NBAライブベッティングlvaptan administered orally once per day.

PackagNBAライブベッティングg

[PTP] 20 tNBAライブベッティングlets (10 tNBAライブベッティングlets × 2), [PTP] 100 tNBAライブベッティングlets (10 tNBAライブベッティングlets × 10)

トルバプタン.jpg

Date of approval for manufacture and sale

February 15, 2022

Date of NHI drug price listNBAライブベッティングg

June 17, 2022

Date of launch

June 17, 2022

Price

491.60 yen/tNBAライブベッティングlet

Manufactured and distributed by

Otsuka Pharmaceutical FacNBAライブベッティングry, Inc.

Comarketed by

Otsuka Pharmaceutical Co., Ltd.


Archives